Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset CMSA
Coverage 92,460 Raw stories ingested 7,972 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 Live Pipeline agents
  • FMP Stock News Fetch every minute running now
  • FMP Forex News Fetch every 5 min 3m ago
  • CoinGecko News Fetch every 5 min 3m ago
  • FIO Stock News Fetch every 10 min 2m ago
  • Patria Stock News Fetch every 10 min 2m ago
  • Editorial rewrite Rewrite every minute 1m ago
  • Asset sync Assets every 1 hour 22m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-07-21 15:45 4d ago
2026-07-21 11:00 5d ago
CMS Energy čeká nižší zisk, vyšší tržby ve 2. čtvrtletí
CMSA CMS Energy
FMP Stock News 78
Original source text
Wall Street expects a year-over-year decline in earnings on higher revenues when CMS Energy (CMS - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 28. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis energy company is expected to post quarterly earnings of $0.63 per share in its upcoming report, which represents a year-over-year change of -11.3%.

Revenues are expected to be $1.95 billion, up 6.2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 6.1% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CMS Energy?For CMS Energy, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -10.40%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that CMS Energy will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CMS Energy would post earnings of $1.11 per share when it actually produced earnings of $1.13, delivering a surprise of +1.80%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CMS Energy doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerNextEra Energy (NEE - Free Report) , another stock in the Zacks Utility - Electric Power industry, is expected to report earnings per share of $1.08 for the quarter ended June 2026. This estimate points to a year-over-year change of +2.9%. Revenues for the quarter are expected to be $7.97 billion, up 18.9% from the year-ago quarter.

The consensus EPS estimate for NextEra has been revised 5% higher over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -0.47%.

This Earnings ESP, combined with its Zacks Rank #2 (Buy), makes it difficult to conclusively predict that NextEra will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
2026-07-13 01:18 13d ago
2026-07-12 20:30 13d ago
Insilico a CMS rozšiřují spolupráci na lék pro CNS
CMSA CMS Energy
FMP Stock News 78
Original source text
, /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.

According to the collaboration agreement, the two parties will jointly advance the co-development of the R&D program by combining Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep therapeutic expertise. Insilico Medicine is eligible to receive up to approximately 1.2 billion RMB in milestone payments plus royalties. This partnership marks a deepening collaboration that leverages both parties' complementary strengths across the full value chain—from drug discovery and clinical development to commercialization.

Mr. Lam Kong, the Chairman, Chief Executive Officer, President and Executive Director of CMS said: "CMS is deeply impressed by Insilico Medicine's capability and productivity in AI drug discovery. We are happy to deepen our collaboration with Insilico Medicine. Insilico Medicine's leadership in AI drug discovery platforms and data-driven R&D is strategically complementary to CMS's capabilities in innovative R&D and clinical translation. In addition, CMS has built solid strengths in clinical development systems and efficiency, regulatory submission expertise, and commercialization network coverage. Our goal never changes: to accelerate the delivery of more clinically meaningful innovations to patients with greater speed and quality, better meeting the growing clinical needs."

"We are delighted to establish another collaboration with China Medical System just three months after our initial announcement," said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. "Our existing partnership, announced earlier this year, has been seamless and productive since its inception. In this new program, we value the input from the CMS commercialization team and are proud of the innovative Mechanism of Action (MoA) identified by PandaOmics, which streamlines the development of high-potential drugs, enhancing translational efficiency, and accelerating the transition of molecules from 'proof of concept' to life-changing patient therapies. We will continue to deepen our multi-dimensional collaboration in pipeline and clinical strategy and global partnerships to provide patients with more differentiated and accessible treatment options."

About CMS

CMS (HKEX stock code:867; SGX stock code: 8A8) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/gastroenterology/ophthalmology/ skin health businesses, bringing economies of scale in specialty fields.

About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com

SOURCE Insilico Medicine